1. Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy.
- Author
-
Navarro F, Casares N, Martín-Otal C, Lasarte-Cía A, Gorraiz M, Sarrión P, Llopiz D, Reparaz D, Varo N, Rodriguez-Madoz JR, Prosper F, Hervás-Stubbs S, Lozano T, and Lasarte JJ
- Subjects
- 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid metabolism, Animals, Cell Line, Tumor, Hydrogen-Ion Concentration, Mice, CD8-Positive T-Lymphocytes metabolism, Immunotherapy, Adoptive methods
- Abstract
The high metabolic activity and insufficient perfusion of tumors leads to the acidification of the tumor microenvironment (TME) that may inhibit the antitumor T cell activity. We found that pharmacological inhibition of the acid loader chloride/bicarbonate anion exchanger 2 (Ae2), with 4,4'-diisothiocyanatostilbene-2,2'-disulfonicacid (DIDS) enhancedCD4
+ andCD8+ T cell function upon TCR activation in vitro , especially under low pH conditions. In vivo , DIDS administration delayed B16OVA tumor growth in immunocompetent mice as monotherapy or when combined with adoptive T cell transfer of OVA-specificT cells. Notably, genetic Ae2 silencing in OVA-specificT cells improvedCD4+ /CD8+ T cell function in vitro as well as their antitumor activity in vivo . Similarly, genetic modification of OVA-specificT cells to overexpress Hvcn1, a selectiveH+ outward current mediator that prevents cell acidification, significantly improved T cell function in vitro , even at low pH conditions. The adoptive transfer of OVA-specificT cells overexpressing Hvcn1 exerted a better antitumor activity in B16OVA tumor-bearingmice. Hvcn1 overexpression also improved the antitumor activity of CAR T cells specific for Glypican 3 (GPC3) in mice bearing PM299L-GPC3tumors. Our results suggest that preventing intracellular acidification by regulating the expression of acidifier ion channels such as Ae2 or alkalinizer channels like Hvcn1 in tumor-specificlymphocytes enhances their antitumor response by making them more resistant to the acidic TME., Competing Interests: No potential conflict of interest was reported by the author(s)., (© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.)- Published
- 2022
- Full Text
- View/download PDF